Addex Therapeutics (ADXN)
(Delayed Data from NSDQ)
$8.67 USD
+0.83 (10.59%)
Updated Jul 5, 2024 03:24 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADXN 8.67 +0.83(10.59%)
Will ADXN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ADXN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADXN
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q3 Loss, Tops Revenue Estimates
ADXN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Misses Revenue Estimates
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
Other News for ADXN
Addex Therapeutics GAAP EPS of -CHF 0.01, revenue of CHF 0.24M
Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript
ADXN Stock Earnings: Addex Therapeutics Reported Results for Q1 2024
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
Addex Convenes Annual General Meeting 2024